We’re driven to save lives

Over the past three decades, Chris has become a world-renowned medical technologist. Companies Chris has worked on have set the industry gold standard for motion preservation, regeneration of cartilage and soft tissue through the use of novel peptides, tissue regeneration using DNA pairs, and stem cell and PRP technologies for use in regenerative medicine. Throughout his career, Chris has represented more than 150 medical device companies in a variety of business transactions including licensing agreements, joint ventures and M&A.

Chris reinvented surgical robotics with the founding and eventual $5.75 billion total exit of Auris Health. Chris has now turned his sights on revolutionizing the way we battle infectious disease, inventing surgical robots that can do what human hands cannot, and bringing technologies aimed to optimize human performance to the world.

Chris has given talks at the Hamlyn Symposium on Medical Robotics, China’s Global Innovation and Entrepreneurship Fair, the U.A.E.’s Innovation Week, Massachusetts General Hospital’s Biotech Funding Panel, LSI’s Emerging MedTech Summit and Harvard University’s Medical and Kennedy Schools. In 2016, Chris was honored by the U.A.E.’s Ministry of Health for his commitment to bringing MedTech innovation to MENA. He has been featured on NBC10, the Wall Street Journal, Boston Business Journal and PE Hub. Companies he has founded have won numerous awards including MedTech Insight Award for Best Technological Innovation, CNBC Disrupter 50, Acquisition International Finance Award for Best Medical Technology VC Firm and Corporate LiveWire M&A Award for Health & Medical Technology Consultancy of the Year.

Nisha Varma brings over 15 years of experience in direct investing, portfolio management, engineering and strategy for major multinational companies. As chief operating officer of BOA Biomedical, Varma focuses on licensing new patents, developing the company strategy, advancing corporate partnerships, overseeing operations, and commercializing new products. Before joining Miraki Innovation, Varma was Vice President at GE Capital’s Private Equity group, where she originated, underwrote and managed equity investments. Before GE, she was an associate at McKinsey & Company, where she advised major companies on marketing and strategic issues. Prior to McKinsey & Company, Varma worked on projects with early stage companies. Varma began her career as a computer engineer at Schlumberger.

Nisha holds a Bachelor of Engineering in Electronics and Communications Engineering from Osmania University, a Master of Engineering in Computer Engineering from Texas A&M University and a Master of Business Administration from Harvard Business School.

Dr. Michael McCurdy brings decades of clinical and research experience to BOA Biomedical. As Chief Medical Officer, Dr. McCurdy provides leadership for BOA’s product development, clinical trial strategies, and ongoing business development and clinical collaborations with academic and commercial centers of excellence. Prior to joining BOA, Dr. McCurdy was Chief of the Department of Medicine and ICU Medical Director at the University of Maryland St. Joseph Medical Center. He continues to serve on the faculty at the University of Maryland School of Medicine, where he created and directed both the critical care medicine fellowship program, one of the premier programs of its kind on the East Coast, and the critical care consult service, which focused on resuscitating clinically unstable patients outside of the ICU. Dr. McCurdy’s active involvement in sepsis-related clinical research has yielded numerous publications, international lectures, and inventions. He completed his undergraduate degree at the University of Notre Dame, medical degree at the University of Texas Medical School at San Antonio, and post-graduate clinical training at the University of Maryland. He is triple board-certified in Emergency Medicine, Internal Medicine, and Critical Care Medicine.

Dr. Donald Ingber heads the Scientific Advisory Board for BOA Biomedical and is on the Board of Directors for BOA Biomedical. Dr. Ingber is the founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, Judah Folkman Professor of Vascular Biology Harvard Medical School, and a professor of Bioengineering at Harvard John A. Paulson School of Engineering & Applied Sciences.

He is a pioneer in the field of biologically inspired engineering and leads a multifaceted effort to develop breakthrough bioinspired technologies to advance healthcare and improve sustainability. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and transitional medicine. He is a member of the National Academy of Medicine, National Academy of Inventors and American Academy of Arts and Sciences, has found four other startup companies and has authored more than 500 publications and 135 patents. Other recent technologies Donald has worked on include an anticoagulant surface coating for medical devices that replaces the need for dangerous blood-thinning drugs, a shear stress-activated nanotherapeutic that targets clot-busting drugs to sites of vascular occlusion, and Human Organs-on-Chips created with microchip manufacturing methods and lined by living human cells that are used to replace animal testing by the pharmaceutical and biotechnology industries.

Donald received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.

Earl was commissioned as Ensign in the U.S. Navy through the Navy ROTC program and also worked as the Damage Control Assistant on USS ROGERS (DD-876) in San Diego. He later volunteered for Basic UDT/SEAL training and was assigned to Underwater Demolition Team Twelve, where he served as Platoon Officer in Charge in Vietnam; Diving Officer; and OIC of the UDT platoon assigned to recover Apollo 16. Earl was an Operations Officer for a Seventh Fleet Naval Special Warfare staff and also in various Naval Special Warfare staff and command assignments; including Naval Special Warfare Group 2, Commanding Officer of Naval Reserve SEAL Team 2, and Commander of the Joint Reserve Unit Iceland Defense Force. He is currently employed as Financial Advisor and Certified Financial Planner, at Century Bank & Trust. His professional licenses include FINRA Series 7, 63, 65 ,66, Chartered Life Underwriter and Chartered Financial Counselor.

Michael Super is one of the scientific founders of the BOA Biomedical technology. Michael also is the lead senior staff scientist at the Wyss Institute for Biologically Inspired Engineering at Harvard University. His research leverages protein engineering to design therapeutics and diagnostic devices to treat cancer and infectious and immunological diseases. Prior to joining the Wyss, Michael spent 17 years in the biotechnology industry, employed at companies ranging from startups to large Pharma. He was the director of the protein biochemistry, immunobiology and hybridoma antibody groups, focusing on the design, development and production of therapeutic antibodies for cancer and autoimmune disease therapy.

Michael received his M.Sc. in Biomolecular Organization at Birkbeck College and his Ph.D. in Medical Immunology at the Institute of Child Health, University of London, followed by postdoctoral work at Harvard in Hematology/Oncology and Infectious disease.

Dr. Keith Crawford is the Director of Clinical Trials and Education at PHEN. He was the former Chief Medical Officer and Chief Scientific Officer at Asclepius labs. Dr. Crawford received his medical degree from University Texas Medical School in Houston and completed a Doctor of Philosophy Cellular, Molecular Biology and Immunology at Harvard University and was selected as Harold Amos Fellow by the Robert Wood Johnson Foundation. After completion of his post-doctoral training, Dr. Crawford worked as a Director of Molecular Orthopedics at Brigham and Women’s Hospital and Harvard Medical School.

Dr. Bertrand Jaber is Chair of the Department of Medicine at St. Elizabeth's Medical Center in Boston and Professor of Medicine at Tufts University School of Medicine. Dr. Jaber has extensive expertise in dialysis device-related research, translational research in cytokine and leukocyte biology in acute and chronic kidney disease, hospital-based outcomes research in kidney disease. He has also made contributions to the field of endotoxin binding in experimental settings in an effort to attenuate host inflammatory responses.

Dr. Nathan Shapiro is the Vice Chair of Emergency Medicine Research at Beth Israel Deaconess Medical Center and a Professor of Medicine at Harvard Medical School. Dr. Shapiro received his medical degree from Temple University School of Medicine, completed an internship year in transitional medicine at Cook County Hospital, followed by residency in Emergency Medicine at the Harvard Affiliated Emergency Medicine. He then received a Master of Public Health in clinical effectiveness from the Harvard School of Public Health.